Biology of Blood and Marrow Transplantation
Volume 13, Issue 6 , Pages 683-690 , June 2007

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease

  • Paul A. Carpenter

      Affiliations

    • Fred Hutchinson CRC, Seattle, Washington
    • University of Washington, Seattle, Washington
    • Corresponding Author InformationCorrespondence and reprint requests: Paul A. Carpenter, MD, Fred Hutchinson CRC, Clinical Research Division, 1100 Fairview Avenue North, Mailstop D5-290, Seattle, WA 98109.
    • ,
  • Paul Hoffmeister

      Affiliations

    • Fred Hutchinson CRC, Seattle, Washington
    • ,
  • Charles H. Chesnut III

      Affiliations

    • University of Washington, Seattle, Washington
    • ,
  • Barry Storer

      Affiliations

    • Fred Hutchinson CRC, Seattle, Washington
    • University of Washington, Seattle, Washington
    • ,
  • Paula M. Charuhas

      Affiliations

    • Seattle Cancer Care Alliance, Seattle, Washington
    • ,
  • Ann E. Woolfrey

      Affiliations

    • Fred Hutchinson CRC, Seattle, Washington
    • University of Washington, Seattle, Washington
    • ,
  • Jean E. Sanders

      Affiliations

    • Fred Hutchinson CRC, Seattle, Washington
    • University of Washington, Seattle, Washington

Received 21 November 2006 ,Accepted 5 February 2007.

References 

  1. Hui SL, Slemenda CW, Johnston CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporosis Int. 1990;1:30–34
  2. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259
  3. Kaste SC, Shidler TJ, Tong X, et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33:435–441
  4. Chan GM. Performance of dual-energy x ray absorptiometry in evaluating bone, lean body mass, and fat in pediatric subjects. J Bone Miner Res. 1992;7:369–374
  5. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray obsorptiometry (DEXA). J Pediatrics. 2004;144:253–257
  6. Bhatia S, Ramsay NK, Weisdorf D, et al. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998;22:87–90
  7. Cooper C, Dennison EM, Leufkens HGM, et al. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res. 2004;19:1976–1981
  8. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001;7:257–264
  9. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:165–174
  10. Laan RF, van Reil PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis (A randomized, controlled study). Ann Intern Med. 1993;119:963–968
  11. Ebeling PR, Thomas DM, Erbas B, et al. Mechanisms of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res. 1999;14:342–350
  12. Gilsanz V, Carlson ME, Roe TF, Ortega JA. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr. 1990;117:238–244
  13. Aisenberg J, Hsieh K, Kalaitzoglou G, et al. Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol. 1998;20:241–245
  14. Schulte CMS, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103:3635–3643
  15. Lane NE. Osteoporosis (An update on glucocorticoid-induced osteoporosis). Rheum Dis Clin North Am. 2001;27:235–253
  16. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation. Biol Blood Marrow Transplant. 2006;6:175–181
  17. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chonic graft-versus-host disease: V (Ancillary Therapy and Supportive Care Working Group Report). Biol Blood Marrow Transplant. 2006;12:375–396
  18. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest. 2002;110:1239–1241
  19. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–952
  20. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Min Res. 2005;20:758–763
  21. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab. 2003;16:887–892
  22. Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab. 2003;19:523–528
  23. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003;142:417–423
  24. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43:1960–1966
  25. Thornton J, Ashcroft DM, Mughal MZ, Elliot RA, O’Neill TW, Symmons D. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child. 2006;91:753–761
  26. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis: 2001 update. American College of Rheumatologists Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthrits Rheum. 2001;44:1496–1503Anonymous.
  27. Bonnick SL. Bone density data: from DPA to DXA and manufacturer to manufacturer. In:  Bonnick SL editors. 2nd ed.. Bone Densitometry in Clinical Practice. vol. 5:Clifton, NJ: Humana Press; 2004;p. 111–126
  28. Pocock NA, Sambrook PN, Nguyen T, Kelly P, Freund J, Eisman JA. Assessment of spinal and femoral bone density by dual x-ray absorptiometry: comparison of Lunar and Hologic instruments. J Bone Miner Res. 1992;7:1081–1084
  29. Brown JJ, Zacharin MJ. Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health. 2005;41:553–557
  30. Wacker W, Barden HS. Pediatric reference data for male and female total body and spine BMD and BMC. Lunar data. Dallas, TX: International Society of Clinical Densitometry; 2001;March 13-17
  31. Plotkin H, Rauch F, Bisohp NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846–1850
  32. Lee Y-S, Low S-L, Lim L-A, Loke K-Y. Cyclic pamidronate infusion improves bone mineralization and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160:641–644
  33. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356–364
  34. Marini JC. Do bisphosphonates make children’s bones better or brittle?. N Engl J Med. 2003;349:423–426
  35. Munns CF, Raunch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779–1786
  36. Weber M, Roschger P, Fratzl-Zleman N, et al. Pamidronate does not adversely affect intrinsic material properties in children with osteogenesis imperfecta. Bone. 2006;39:616–622
  37. Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res. 2006;21:374–379
  38. Sambrook P. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician. 2006;35:801–803
  39. Medical Advisory Council. Bisphosphonates and the risk of osteonecrosis of the jaw in osteogenesis imperfecta. www.oif.org; August 3, 2006.
  40. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  41. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type 1. J Clin Endocrinol Metab. 2005;90:4051–4056
  42. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19:55–79
  43. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16:398–405
  44. Mauseth RS, Kelly BE, Sanders JE. Bone mineral density in pediatric marrow transplant patients. Pediatr Res. 2001;49:82A
  45. Stallings VA. Calcium and bone health in children: a review. (review) Am J Ther. 1997;4:259–273
  46. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–333
  47. Khosla S, Melton LJ, Riggs BL. Estrogens and bone health in men. (review) Calcif Tissue Int. 2001;69:189–192

PII: S1083-8791(07)00146-2

doi: 10.1016/j.bbmt.2007.02.001

Biology of Blood and Marrow Transplantation
Volume 13, Issue 6 , Pages 683-690 , June 2007

Article Tools

* Image Usage & Resolution